July 1, 2024 07:05 AM EDT
Deals
R&D

Ei­sai takes over de­vel­op­ment of ADC af­ter Bris­tol My­ers ends $650M col­lab­o­ra­tion

Katherine Lewin

News Reporter

Due to Bris­tol My­ers Squibb’s port­fo­lio pri­or­i­ti­za­tion ef­forts, Ei­sai is tak­ing back an an­ti­body-drug con­ju­gate that they orig­i­nal­ly teamed up on …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Dan­ish biotech Gubra touts ear­ly weight loss da­ta in hot amylin field

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

J&J takes 340B fight with fed­er­al gov­ern­ment to court

Adap­ti­m­mune's sec­ond T cell re­cep­tor cell ther­a­py for rare sar­co­mas pass­es piv­otal test

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times